PHARMAC is pleased to announce the approval of an agreement with bioCSL (NZ) Ltd for a number of pharmaceuticals (the “Agreement”).  This was the subject of a consultation letter dated 24 October 2014.

A summary of the decision is provided below, which is as was consulted upon. For further details please refer to the consultation letter.

• Solifenacin succinate (Vesicare) will continue to be listed Section B and Part II of Section H of the Pharmaceutical Schedule, but the price and subsidy will reduce from 1 January 201
• Vesicare will have subsidy and delisting protection until 1 July 2018.
• A confidential rebate will apply to Vesicare, reducing the net price paid by the Funder.
• The current Special Authority for Vesicare is unchanged; it remains second line to treat patients non-responsive to oxybutynin.

For more details, go to: http://www.pharmac.health.nz/news/notification-2014-11-27-multiproduct/